Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) has provided an update.
Guangzhou Baiyunshan Pharmaceutical Holdings Company, through its subsidiary GP Corp., announced the acquisition of 100% equity in a target company for RMB 500.50 million. This strategic investment strengthens its market positioning and highlights its commitment to growing operational scale, marking a significant step in expanding its footprint within the pharmaceutical sector.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
More about Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company operates within the pharmaceutical industry, focusing on the production and distribution of traditional Chinese medicine, modern pharmaceutical products, and healthcare products. The company is a key player in the healthcare sector aiming to enhance its market presence and expand its operational capabilities.
Average Trading Volume: 1,195,894
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$43.87B
For a thorough assessment of 0874 stock, go to TipRanks’ Stock Analysis page.